top of page

AACR24: EpicentRx’s phase 2a using TGF-β trap to overcome checkpoint resistance

EpicentRx CEO Tony Reid and MD Andersen investigator Anthony Conley describe the data presented at AACR showing how TGF-β might be used to turn cold tumors hot.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page